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Abstract
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human
cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has
not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified
as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-
expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies
designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the
most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the
foreseeable clinical applications of CD105 in human cancer are discussed.
Background
The availability of new and more sophisticated technolo-
gies, together with the improved knowledge on tumor-
host interactions, have allowed the identification and
characterization of different tumor-associated antigens
(TAA) to be used as molecular targets for immunothera-
peutic approaches in patients with solid or hematologic
malignancies. Prompted by encouraging pre-clinical evi-
dences, significant clinical results in cancer treatment have
been obtained through antibody-based therapeutic regi-
mens, such as those that target CD20 on malignant B cells
[1] or HER2 in breast cancer [2]. However, due to the het-
erogeneous expression of TAA in neoplastic tissues, these
approaches raise some critical issues such as "patients' eli-
gibility" to specific TAA-based treatment modalities.
Moreover, the efficacy of TAA targeting is frequently lim-
ited by the inadequate accessibility of therapeutic anti-
bodies or their derived molecules within the tumor mass
[3].
Currently, great interest is focused on angiogenesis and on
its potential clinical implications in cancer, and vascular
targeting represents a highly promising alternative to the
direct engagement of therapeutic TAA on neoplastic cells
[4,5]. Among potential therapeutic strategies to induce
tumor regression by blocking tumor blood supply, an
intriguing approach relies on the selective targeting of cell
surface molecules over-expressed on endothelial cells of
tumor-associated blood vessels [4,5]. In this setting,
emerging in vitro and in vivo pre-clinical evidence identi-
fies CD105 as a cell membrane glycoprotein representing
a prime vascular target to implement innovative antibody-
based diagnostic and therapeutic strategies shared by
human neoplasia of different histotype.
Biological features of CD105
Tissue distribution
CD105 is a 180 kDa transmembrane glycoprotein consti-
tutively phosphorylated [6-10], with a marked tissue-spe-
cificity [11]. Supporting this notion, CD105 is
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its promoter is strongly and selectively active in endothe-
lial cells [14,15]. Consistently, elevated levels of CD105
expression were detected on human microvascular
endothelium [16] and on vascular endothelial cells in tis-
sues undergoing active angiogenesis, such as regenerating
and inflamed tissues or tumors [11,12,17-21]. However,
CD105 was also weakly expressed on selected non-
endothelial cells of different histotype (Table 1 and ref
[22,23] for review).
In solid neoplasia, CD105 is present on endothelial cells
of both peri- and intra-tumoral blood vessels and on
tumor stromal components [11,17,22-24]. In particular,
CD105 is largely expressed in small and likely immature
tumor vessels as demonstrated in breast, prostate and gas-
tric cancer [24-26]; rarely, CD105 is expressed in the cyto-
plasm of neoplastic cells [23]. In lung carcinoma, staining
for CD105 was reported to be strong at the areas of active
angiogenesis including tumor edge, while it was less
intense in the central area of the tumor and not detectable
in the adjacent normal tissue [12].
Functional activity
CD105 is a component of the receptor complex of Trans-
forming Growth Factor (TGF)-β [27-29], a pleiotropic
cytokine involved in cellular proliferation, differentiation
and migration [30]. It binds several components of the
TGF-β superfamily [27,29]. Interestingly, binding of TGF-
β1 to CD105 reduces the levels of CD105 phosphoryla-
tion [10] and the levels of CD105 expression modulate
the effects of TGF-β1 [28,31-35]. In this respect, it is of
interest that the inhibition of CD105 expression
enhanced the ability of TGF-β1 to suppress growth, migra-
tion and capacity to form capillary tubes of cultured
endothelial cells [32].
In the absence of TGF-β1, CD105 shows an anti-apoptotic
effect in endothelial cells under hypoxic stress, suggesting
for a protective role of CD105 against pro-apoptotic fac-
tors [36].
In addition, the discovery that levels of CD105 regulate
the expression of different components of the extracellu-
lar matrix including fibronectin, collagen, PAI-1 and lum-
ican [34,37,38], is also suggestive for a crucial role of
CD105 in cellular transmigration [38].
Modulation
Different environmental factors and cytokines involved in
angiogenesis modulate CD105 expression. The levels of
CD105 protein, mRNA and promoter activity are up-reg-
ulated by hypoxia [39] and by TGF-β1 [28,39-41], which
cooperate to induce the expression of CD105 at transcrip-
tional level [39]. Instead, TNF-α down-regulates CD105
protein levels but it has no effect at the transcriptional
level [42].
Furthermore, CD105 expression was up-regulated on
human umbilical vein endothelial cells (HUVEC) infected
with a recombinant adenovirus carrying a constitutively
active form of activin receptor-like kinase (ALK)-1, a type
I TGF-β receptor [43].
Supporting the in vivo modulation of CD105 by pro-ang-
iogenetic stimuli, elevated levels of CD105 were associ-
ated with high levels of vascular endothelial growth factor
in non-small cell lung cancer lesions positive for angi-
opoietin-2, a regulatory factor of survival of endothelial
cells, considerably expressed at sites of vascular remodel-
ling and in highly vascularized tumors [44].
CD105 and vascularization
Even if its functional role is not fully understood, several
findings suggest for the involvement of CD105 in angio-
genesis and vascular development, and in maintaining
vessel wall integrity.
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endothelial cells in culture [11-13] and on endothelial
cells of angiogenetic blood vessels [11,12,24,33,45]. Fur-
thermore, CD105 knockout mice died of defective vascu-
lar development during early gestation [46], as observed
in TGF-β1- and ALK-1-null mice [47,48]. In particular,
CD105 null mice showed important structural defects in
the primitive vascular plexus of the yolk sac that prevented
the formation of normal mature vessels [46]. Addition-
ally, both in humans and mice, CD105 gene mutations
are associated with hereditary hemorrhagic telangiectasia
type 1, an inherited disease characterized by arteriovenous
malformations and bleedings [49-51]. Finally, CD105 has
been most recently suggested as a regulator factor of nitric
oxide-dependent vasodilatation. In fact, the levels of
CD105 expression modulated the amounts of endothelial
nitric oxide synthase (eNOS) in kidney and femoral arter-
ies of mice. Furthermore, over-expression or suppression
of CD105 in cultured endothelial cells induced a marked
increase or decrease in the protein levels of eNOS, respec-
tively [52].
Interestingly, an increment in microvessel density, as
determined by immunohistochemical staining for
CD105, was found during the progressive stages of color-
ectal carcinogenesis [53]. In line with this finding, the
assessment of neovascularization by CD105 staining was
found to represent a potential predictor of prognosis in
different solid malignancies (Table 2 and Table 3). For
instance, the CD105-positive blood vessels count was
prognostic for survival in patients with prostate cancer of
Gleason score 5–7 [25], and correlated with overall sur-
vival of node-negative patients affected by breast carci-
noma [54,55].
mAb directed to CD105 but not to the pan-endothelial
marker CD34 revealed an inverse correlation between
intra-tumoral microvessel density and apoptotic index of
neoplastic cells in non-small cell lung cancer patients
[56]. Since angiogenesis is crucial for tumor development
and progression [57], this finding provided supportive
evidence to the usefulness of CD105 targeting in antiang-
iogenetic therapy of cancer [56].
Table 2: Intra-tumor microvessel density determined by immunohistochemical staining for CD105: an indicator of poor prognosis in 
patients with solid neoplasia.
Tumor histotype References






Nonseminomatous testicular germ cell tumors [83]
Non-small cell lung cancer [56, 84]
Prostate cancer [25]
Renal cell carcinoma [85]
Squamous cell carcinoma of the oral cavity [19]
Table 3: CD105 as a marker of survival in patients with solid tumors of different histotype.
Tumor histotype CD105-MVDa correlation with survival References
Breast carcinoma The number of CD105-positive microvessels correlated significantly (p = 0.001) with poor 
overall survival.
[55]
Colorectal cancer Patients with CD105-MVD above the median showed the worst prognosis; similar results 
were obtained when CD105-MVD was divided in quartiles.
[78]
Endometrial carcinoma Patients with the lower quartiles for CD105-MVD showed reduced survival compared to 
those with the higher quartiles.
[80]
Non-small cell lung cancer 5-year survival rate of patients with the lower CD105-MVD was higher compared to that 
of patients with the higher CD105-MVD.
[84]
Prostate cancer Median survival time were shorter for patients with CD105-MVD above the median. [25]
aCD105-MVD, intratumor microvascular density as determined by anti-CD105 monoclonal antibodies.Page 3 of 7
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Ex vivo background
Selected anti-CD105 monoclonal antibodies (mAb) sig-
nificantly inhibit the proliferation of cultured human
microvascular and macrovascular endothelial cells
[11,58,59], thus supporting the notion that CD105 is a
promising vascular target to implement innovative anti-
body-based therapeutic strategies in human cancer. Note-
worthy, differences in the growth suppression of
endothelial cells have been found among 4 anti-CD105
mAb defining different epitopes [59]; nevertheless, TGF-
β1 and each of the 4 anti-CD105 mAb showed synergistic
suppression of HUVEC proliferation [59].
A bispecific single-chain diabody directed to the adenovi-
rus fiber knob domain and to CD105 was shown to be
effective in enhancing adenovirus transduction in
HUVEC, thus sustaining the use of CD105 protein as tar-
get for therapeutic gene transfer in endothelial cells [60].
Along this line, a vector constructed with the CD105 pro-
moter was efficiently utilized to deliver gene expression
specifically to endothelial cells of mouse blood vessels
[61]. Additionally, human CD105 promoter fragments
were successfully utilized in pigs to drive CD59 expression
in the small vessels of heart, kidney and lung, but not in
the large vessels of these organs [62].
Most recently, another bispecific single-chain diabody
was proposed for therapeutic approaches aiming to
destroy tumor-associated vasculature. This engineered
antibody is directed to human CD105 as well as CD3 and
it is effective to mediate killing of CD105-positive
endothelial cells by cytotoxic T lymphocytes [63]. An
alternative strategy of CD105 targeting for anti-angio-
genetic treatment of cancer might derive by the use of con-
ditionally replicating adenoviruses (CRAD). In fact,
CRAD obtained by utilizing Flk-1 and CD105 regulatory
elements have been transcriptionally targeted towards
proliferating endothelial cells, with specificity and efficacy
in killing HUVEC [64].
In vivo diagnostic targeting
The over-expression of CD105 on proliferating endothe-
lial cells of the tumour vasculature suggested that CD105
might also represent a good target for the immunoscintig-
raphy of tumors. In keeping with this idea, targeting of
CD105 by radiolabeled mAb was described as a safe and
effective procedure to image tumors in animal models
[13,65]. The intravenous administration of a 125I-labeled
anti-CD105 mAb efficiently imaged spontaneous mam-
mary adenocarcinomas in dogs. The immunoscintigraphy
performed 8 hours after mAb injection demonstrated that
the uptake of the radiolabeled mAb was rapid and intense,
and no systemic side effects were observed in the injected
dogs during a 3 months follow-up after imaging proce-
dures [13]. Consistently, the scintigraphy performed 15
minutes after administration of low doses of 111In-labeled
anti-CD105 mAb in C57BL/6 mice demonstrated an accu-
mulation of radioactivity in xenografts of human
melanoma. The autoradiography and immunohistology
showed a marked concentration of the mAb in the periph-
ery of the tumor mass with an heterogeneous distribution
in its centre. Noteworthy, the 97% of the injected dose of
the radiolabeled anti-CD105 mAb was removed from the
circulation within 15 min, and the blood half-life of the
anti-CD105 mAb was estimated to be <1 minute [65].
The immunoscintigraphy performed after renal artery per-
fusion of 99Tcm-labeled anti-CD105 mAb in the freshly
excised kidney from a patient with renal carcinoma iden-
tified 2 distinct hot spots of radioactivity, which matched
the positions of the tumors, as demonstrated by the sub-
sequent histopathologic examination; noteworthy, only
one of the two tumor masses was identified by a pre-sur-
gery magnetic resonance imaging scan [66].
In vivo therapeutic targeting
Targeting of CD105, as therapeutic antiangiogenetic
approach in cancer, has been extensively investigated in
severe combined immunodeficiency [SCID] mice bearing
human breast tumors. The results of these studies demon-
strated a long lasting suppression of tumor growth and
metastasis by systemic administration of radiolabeled or
immunotoxin-conjugated anti-CD105 mAb [67-69]. Fur-
thermore, naked anti-CD105 mAb, which reacted strongly
with proliferating human endothelial cells but weakly
with murine endothelial cells, showed synergism with
conventional chemotherapeutic regimens in a human
skin/SCID mouse chimera model [70]. Interestingly, in all
these animal models the anti-tumor efficacy and the anti-
metastatic activities were identified in the ability of the
anti-CD105 mAb to inhibit tumor-associated angiogen-
esis and/or to obliterate tumor-associated vasculature [67-
70].
Conclusions and future directions
A number of convincing experimental findings suggest
that selected anti-CD105 mAb can strongly localize to the
endothelium of tumor-associated vasculature and that
they are efficient to inhibit tumor angiogenesis, tumor
growth and metastasis in mice, pointing to CD105 as a
suitable vascular target to implement antibody-based
therapeutic approaches in cancer.
However, concern about the therapeutic applications of
anti-CD105 mAb and their derived molecules in cancer
patients emerged by discrepancies observed in the expres-
sion of CD105 within normal and tumor tissues [71-74].
In this respect, it has been suggested that not all anti-
CD105 mAb are useful for anti-angiogenetic targetingPage 4 of 7
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culature of normal tissues [45,59,66,73]. Based on these
findings, the comparative evaluation of the reactivity of a
large panel of anti-CD105 mAb in the same tumor speci-
men has been proposed to identify the most reactive with
tumor endothelium [45].
Nevertheless, the information on CD105 so far obtained
by ex vivo studies and in animal models warrants addi-
tional efforts to further define the most appropriate ther-
apeutic setting [s] for CD105 in human cancer, and to
translate pre-clinical evidences into phase I/II clinical
trials.
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